Jan Van Droogenbroeck

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Hagop M. Kantarjian, Neil P. Shah, Jörge E. Cortes et al. · Blood · 2011 · 605 citations · Full text

Medicine, Hematology, Oncology +8

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Roman Hájek, Tamás Masszi, Maria Teresa Petrucci et al. · Leukemia · 2016 · 119 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Recommendations for the management of the haematological and onco‐haematological aspects of Gaucher disease¹

Derralynn Hughes, Maria Domenica Cappellini, Marc Berger et al. · British Journal of Haematology · 2007 · 87 citations · Full text

Medicine, Hematology, Pathology +17

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

Charles Dumontet, Cyrille Hulin, Meletios Α. Dimopoulos et al. · Leukemia · 2018 · 74 citations · Full text

Medicine, Infectious Diseases, Oncology +13